Last 47 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.15 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 8.39 | 8.13 | 21.35 | 1.84 | 10.36 | 12.98 | 5.17 | 0.86 | 1152.76 | 187.32 | 133.92 | 3.45 | 29.84 | 50.87 | 12.68 | 23.34 | 5007.92 | 31.91 | 48.09 | 36.39 | 113.06 |
| — | -37.4% | +312.9% | +114.5% | -99.1% | -93.1% | -96.1% | -75.1% | +3763.4% | +268.3% | +956.0% | -85.2% | -99.4% | +59.4% | -73.6% | -35.9% | +4329.5% | -98.7% | -54.9% | -61.9% | +1515.3% | |
| P/B Ratio | 8.36 | 3.67 | 54.85 | 6.67 | 23.24 | 9.68 | 1.54 | 0.78 | 1.60 | 1.66 | 2.07 | 2.37 | 1.77 | 1.47 | 1.57 | 1.69 | 2.03 | 1.74 | 2.54 | 3.28 | 4.78 |
| — | -62.1% | +3453.4% | +753.2% | +1351.0% | +484.1% | -25.3% | -67.0% | -9.4% | +12.8% | +31.2% | +40.2% | -12.9% | -15.8% | -38.0% | -48.4% | -57.5% | -72.2% | -41.5% | -70.5% | +19.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 82.9% | 100.0% | -162.2% | -352.2% | -470.9% | -58.8% | -2521.3% | -176.8% | -24.1% | 97.6% | 71.6% | -931.5% | -283.8% | -695.6% | -98295.2% | -586.2% | -460.9% | -201.2% | -372.2% |
| — | +128.4% | +117.6% | +270.0% | +93.6% | -99.2% | -1850.7% | -160.3% | -3620.1% | +81.0% | +91.5% | +114.0% | +100.1% | -58.9% | +38.4% | -245.8% | -26306.1% | +93.3% | +15.5% | +54.1% | -908.7% | |
| Operating Margin | -245.2% | -156.0% | -883.2% | -56.7% | -325.4% | -1440.6% | -1635.1% | -152.2% | -107649.2% | -14016.2% | -5902.3% | -39.9% | -940.1% | -1527.3% | -517.3% | -970.7% | -136952.4% | -852.5% | -749.5% | -333.7% | -633.4% |
| — | +89.2% | +46.0% | +62.8% | +99.7% | +89.7% | +72.3% | -281.5% | -11351.0% | -817.7% | -1040.9% | +95.9% | +99.3% | -79.2% | +31.0% | -190.9% | -21521.1% | +94.2% | +14.4% | +42.2% | -4528.1% | |
| Net Margin | -395.0% | -153.3% | -882.4% | -22.7% | -333.0% | -1487.8% | -1633.5% | -148.3% | -101870.5% | -13178.8% | -5458.1% | -31.4% | -843.7% | -1395.6% | -497.8% | -929.3% | -132681.0% | -840.2% | -746.0% | -332.3% | -630.7% |
| — | +89.7% | +46.0% | +84.7% | +99.7% | +88.7% | +70.1% | -371.9% | -11974.5% | -844.3% | -996.5% | +96.6% | +99.4% | -66.1% | +33.3% | -179.6% | -20938.4% | +94.2% | +14.5% | +39.3% | -5168.6% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -198.1% | -33.2% | -157.6% | -27.6% | -153.9% | -130.5% | -77.4% | -29.3% | -30.5% | -25.7% | -19.3% | -5.3% | -11.8% | -11.2% | -14.5% | -15.7% | -12.7% | -10.9% | -9.5% | -7.3% | -6.5% |
| — | +74.5% | -103.7% | +5.8% | -404.8% | -407.9% | -301.8% | -450.7% | -157.5% | -128.7% | -33.1% | +66.0% | +6.5% | -2.8% | -52.6% | -115.6% | -94.4% | -23.8% | +13.9% | +51.5% | -461.5% | |
| ROA | -60.6% | -9.4% | -14.9% | -2.9% | -12.2% | -22.5% | -25.1% | -13.6% | -17.4% | -16.4% | -13.2% | -3.8% | -8.6% | -8.0% | -10.0% | -11.6% | -10.0% | -8.9% | -7.8% | -5.9% | -5.3% |
| — | +58.0% | +40.8% | +78.7% | +30.2% | -37.0% | -90.7% | -260.8% | -102.8% | -104.6% | -31.6% | +67.6% | +14.2% | +9.8% | -29.0% | -95.5% | -88.9% | -23.4% | +7.4% | +44.4% | -525.1% | |
| ROIC | — | — | — | — | — | — | — | -44.8% | -30.3% | -23.2% | -18.8% | -6.1% | -14.2% | -15.0% | -15.6% | -19.5% | -15.9% | -12.7% | -10.9% | -8.5% | -8.9% |
| — | — | — | — | — | — | — | -630.8% | -113.3% | -54.8% | -20.5% | +68.5% | +10.7% | -18.0% | -44.2% | -128.5% | -78.9% | +5.7% | +24.7% | +59.6% | -204.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.81 | 0.15 | 16.33 | 2.81 | 1.46 | 1.10 | 0.50 | 0.26 | 0.22 | 0.17 | 0.12 | 0.14 | 0.10 | 0.09 | 0.12 | 0.12 | 0.05 | 0.04 | 0.05 | 0.05 | 0.05 |
| — | -86.6% | +3173.7% | +977.4% | +566.6% | +560.3% | +330.1% | +87.6% | +128.2% | +79.4% | -0.9% | +14.1% | +87.0% | +113.6% | +159.0% | +155.7% | +5.0% | -11.8% | -0.2% | -28.2% | -19.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.54 | 3.19 | 3.22 | 3.54 | 2.86 | 2.77 | 3.08 | 3.75 | 3.75 | 3.85 | 4.60 | 5.39 | 6.12 | 8.09 | 5.68 | 5.94 | 10.09 | 12.67 | 13.62 | 10.82 | 11.15 |
| — | +14.9% | +4.7% | -5.4% | -23.6% | -28.1% | -33.1% | -30.5% | -38.8% | -52.4% | -19.0% | -9.2% | -39.3% | -36.1% | -58.3% | -45.2% | -9.5% | +35.7% | +37.8% | +50.3% | +20.6% | |
| Quick Ratio | 3.54 | 3.19 | 3.22 | 3.54 | 2.86 | 2.77 | 3.08 | 3.75 | 3.75 | 3.85 | 4.60 | 5.39 | 6.12 | 8.09 | 5.68 | 5.94 | 10.09 | 12.67 | 13.62 | 10.82 | 11.15 |
| — | +14.9% | +4.7% | -5.4% | -23.6% | -28.1% | -33.1% | -30.5% | -38.8% | -52.4% | -19.0% | -9.2% | -39.3% | -36.1% | -58.3% | -45.2% | -9.5% | +35.7% | +37.8% | +50.3% | +20.6% | |
| Interest Coverage | -24.94 | -18.79 | -22.30 | -0.92 | -9.47 | -25.35 | -33.34 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EDIT stock.
Editas Medicine, Inc.'s current P/E is -4.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Editas Medicine, Inc.'s current operating margin is -245.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Editas Medicine, Inc.'s business trajectory between earnings reports.